Complications associated with immunotherapy for brain metastases

Area of Science:

• Neuro-oncology
• Immunotherapy
• Clinical Trials

Background:

• Brain metastases historically have limited survival.
• Immune checkpoint inhibitors are emerging as a treatment for brain metastases, particularly in melanoma.
• Immune-related adverse events present unique challenges in managing brain metastases.

Purpose of the Study:

• To review current knowledge on immunotherapy for brain metastases.
• To identify limitations in understanding treatment-related neurologic toxicities.
• To outline future research directions for immunotherapy in brain metastases.

Main Methods:

• Review of retrospective studies.
• Analysis of prospective clinical trials.
• Examination of case studies.

Main Results:

• Immune checkpoint inhibitors demonstrate intracranial activity and durable responses in brain metastases.
• Immune therapy can worsen edema and increase radiation necrosis risk.
• Neurologic toxicities are expected to increase with broader eligibility for immunotherapy.

Conclusions:

• Enhanced understanding of neurologic toxicities is vital.
• Heightened awareness is necessary for mitigating treatment-related morbidity and mortality.
• Multidisciplinary care is essential for patients receiving immunotherapy for brain metastases.